Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F17%3AE0106759" target="_blank" >RIV/00843989:_____/17:E0106759 - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/17:A1801L7R

Result on the web

<a href="http://dx.doi.org/10.1002/hon.2351" target="_blank" >http://dx.doi.org/10.1002/hon.2351</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/hon.2351" target="_blank" >10.1002/hon.2351</a>

Result language

angličtina

Original language name

Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity

Original language description

Proteasome inhibitors are the backbone in the treatment of multiple myeloma with 3 of its representatives (bortezomib, carfilzomib, and ixazomib) having already been approved. There is a different situation altogether in the treatment of amyloid light chain (AL) amyloidosis where owing to the rarity of this entity neither of these drugs has currently gained approval. Amyloid light chain plasma cells are possibly more vulnerable to bortezomib than myeloma plasmocytes because of a slightly distinct mechanism of action, which is described in depth in this manuscript. Bortezomib is highly active and rapidly effective as a single agent and even more potent in combination with dexamethasone and alkylators. Bortezomib-based regimens have become a standard part of the initial treatment of AL amyloidosis in the majority of centers. We have reviewed all available data on bortezomib in various combinations and settings. Carfilzomib seems to be effective but also toxic in these fragile patients with a high rate of cardiac events. Oral ixazomib has shown a surprisingly high efficacy with manageable toxicity and has received the Food and Drug Administration Breakthrough Therapy designation in 2014 for relapsed AL amyloidosis patients. In this review we have comprehensively described the current available knowledge of these 3 proteasome inhibitors and their use in AL amyloidosis.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Hematological oncology

ISSN

0278-0232

e-ISSN

1099-1069

Volume of the periodical

35

Issue of the periodical within the volume

4

Country of publishing house

US - UNITED STATES

Number of pages

12

Pages from-to

408-419

UT code for WoS article

000418404300002

EID of the result in the Scopus database

2-s2.0-85038441543